Meds

Patients on Antipsychotics Not Properly Monitored

Patients on Antipsychotics Not Properly Monitored

According to a report in the January 2010 Archives of General Psychiatry, Medicaid patients who take second-generation antipsychotic medications are not appropriately assessed for metabolic risks.

 Drugs like risperidone (trade name Risperdal) and olanzapine (trade name Zyprexa) have been proven to increase the risk for high blood glucose, increasing a likelihood of diabetes.

Patients on Antipsychotics Not Properly Monitored

January 28, 2010 — According to a report in the January 2010 Archives of General Psychiatry, Medicaid patients who take second-generation antipsychotic medications are not appropriately assessed for metabolic risks.

 Drugs like risperidone (trade name Risperdal) and olanzapine (trade name Zyprexa) have been proven to increase the risk for high blood glucose, increasing a likelihood of diabetes.

In 2003, the American Diabetes Association and American Psychiatric Association published a joint statement with a monitoring protocol for all patients taking these drugs. Yet researchers at the University of Colorado who examined laboratory claims from Medicaid enrollees in California, Missouri and Oregon found that the protocol was not followed between 2002 and 2005.

Nor did an FDA warning have any impact on increased glucose testing. The authors concluded: “More effort is needed to ensure that patients who receive second-generation antipsychotic drugs are screened for diabetes and dyslipidemia and monitored for potential adverse drug effects, beginning with baseline testing of serum glucose and lipids, so that patients can receive appropriate preventive care and treatment.”

Source: http://www.newswise.com

Leave a Reply